BC
VERV

Bridgefront Capital’s Verve Therapeutics VERV Stock Holding History

Bridgefront Capital’s Portfolio VERV Stock Details VERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-22,706
Closed -$111K – 728
2024
Q2 		$111K Buy
+22,706
New +$143K 0.05% 447

Other funds holding VERV

AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return

Bridgefront Capital's VERV Position: Q3 2024 in Review

Bridgefront Capital sold out of Verve Therapeutics (VERV) in Q3 2024, closing a stake of 22,706 shares — an estimated $111K sold.

Bridgefront Capital first reported a position in VERV in Q2 2024 and held it in 1 quarter. The position peaked at $111K in Q2 2024. 174 funds tracked by Wall St. Rank hold VERV as of Q3 2024.

  • Bridgefront Capital reported no remaining Verve Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Bridgefront Capital sold 22,706 Verve Therapeutics shares in Q3 2024, an estimated $111K.
  • Bridgefront Capital first reported a position in Verve Therapeutics in Q2 2024 and held it in 1 quarter.
  • Bridgefront Capital's Verve Therapeutics position peaked at $111K in Q2 2024.
  • 174 funds tracked by Wall St. Rank held Verve Therapeutics as of Q3 2024.

Based on Bridgefront Capital's 13F filing for Q3 2024, filed 14 Nov 2024.